SRTA vs UNH vs CVS vs HUM vs MCK

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -20. 7% for Strata Critical Medical, Inc. (SRTA). Strata Critical Medical, Inc. (SRTA) offers the better valuation at 10. 7x trailing P/E, making it the more compelling value choice. Analysts rate Strata Critical Medical, Inc. (SRTA) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Strata Critical Medical, Inc.

(SRTA) is the cheapest at 10. 7x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -43. 3% for Humana Inc. (HUM). Over 10 years, the gap is even starker: MCK returned +348. 1% versus SRTA's -45. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Strata Critical Medical, Inc. 's 2. 47β — meaning SRTA is approximately 5620% more volatile than MCK relative to the S&P 500. On balance sheet safety, Strata Critical Medical, Inc. (SRTA) carries a lower debt/equity ratio of 1% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -20. 7% for Strata Critical Medical, Inc. (SRTA). On earnings-per-share growth, the picture is similar: Strata Critical Medical, Inc. grew EPS 242. 9% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, HUM leads at 11. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Strata Critical Medical, Inc.

(SRTA) is the more profitable company, earning 21. 0% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus -11. 3% for SRTA. At the gross margin level — before operating expenses — SRTA leads at 20. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CVS Health Corporation (CVS) trades at 12.

2x forward P/E versus 27. 7x for Humana Inc. — 15. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SRTA: 35. 8% to $7. 25.

In this comparison, CVS (3.

1% yield), UNH (2. 4% yield), HUM (1. 4% yield), MCK (0. 4% yield) pay a dividend. SRTA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Strata Critical Medical, Inc. (SRTA) carries a higher beta of 2. 47 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, SRTA: -45. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SRTA (Industrials) and UNH (Healthcare) and CVS (Healthcare) and HUM (Healthcare) and MCK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SRTA is a small-cap deep-value stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; HUM is a mid-cap quality compounder stock; MCK is a mid-cap high-growth stock. UNH, CVS, HUM pay a dividend while SRTA, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.